Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the treatment of patients with HER2-negative metastatic breast cancer.
This is written in the approval document as:
In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.
Citation
Bevacizumab 10mg/kg - 14 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-negative | Invasive Breast Carcinoma | Bevacizumab, Paclitaxel |